Crestline Management’s Idexx Laboratories IDXX Stock Holding History

Crestline Management’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-3,537	Closed	-$1.46M	–	305
2024 Q4	$1.46M	Buy	+3,537	New	+$1.55M	0.05%	341

Other funds holding IDXX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Crestline Management's IDXX Position: Q1 2025 in Review

Crestline Management sold out of Idexx Laboratories (IDXX) in Q1 2025, closing a stake of 3,537 shares — an estimated $1.46M sold.

Crestline Management first reported a position in IDXX in Q4 2024 and held it in 1 quarter. The position peaked at $1.46M in Q4 2024. 1,142 funds tracked by Wall St. Rank hold IDXX as of Q1 2025.

Crestline Management reported no remaining Idexx Laboratories position as of Q1 2025 after selling out during the quarter.
Crestline Management sold 3,537 Idexx Laboratories shares in Q1 2025, an estimated $1.46M.
Crestline Management first reported a position in Idexx Laboratories in Q4 2024 and held it in 1 quarter.
Crestline Management's Idexx Laboratories position peaked at $1.46M in Q4 2024.
1,142 funds tracked by Wall St. Rank held Idexx Laboratories as of Q1 2025.

Based on Crestline Management's 13F filing for Q1 2025, filed 15 May 2025.